Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (Cd4+CD25hi and CD4+FoxP3+) T cells

European Journal of Immunology

Volumn 35, Issue 12, 2005, Pages 3694-3703

  Coles, Alasdair J ^a,b   Thompson, Sara ^a   Cox, Amanda L ^a   Curran, Suzanne ^a   Gurnell, Elli M ^a   Chatterjee, V Krishna ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Autoimmunity; DHEA; Human; T cells

Indexed keywords

FLUDROCORTISONE; GAMMA INTERFERON; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; MESSENGER RNA; PRASTERONE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ADDISON DISEASE; ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TREATMENT WITHDRAWAL;

ADDISON DISEASE; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADULT; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DEHYDROEPIANDROSTERONE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY;

EID: 29744469426     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200526128     Document Type: Article

References (37)

1. Kimonides, V. G., Spillantini, M. G., Sofroniew, M. V., Fawcett, J. W. and Herbert, J., Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience 1999. 89: 429-436.
2. Orentreich, N., Brind, J. L., Rizer, R. L. and Vogelman, J. H., Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 1984. 59: 551-555.
3. Barrett-Connor, E., Khaw, K. T. and Yen, S. S., A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N. Engl. J. Med. 1986. 315: 1519-1524.
4. Ebeling, P. and Koivisto, V. A., Physiological importance of dehydroepiandrosterone. Lancet 1994. 343: 1479-1481.
5. Sambrook, P., Birmingham, J., Champion, D., Kelly, P., Kempler, S., Freund, J. and Eisman, J., Postmenopausal bone loss in rheumatoid arthritis: Effect of estrogens and androgens. J. Rheumatol. 1992. 19: 357-361.
6. Morales, A. J., Nolan, J. J., Nelson, J. C. and Yen, S. S., Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 1994. 78: 1360-1367.
7. Morales, A. J., Haubrich, R. H., Hwang, J. Y., Asakura, H. and Yen, S. S., The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin. Endocrinol. (Oxf.) 1998. 49: 421-432.
8. Casson, P. R., Santoro, N., Elkind-Hirsch, K., Carson, S. A., Hornsby, P. J., Abraham, G. and Buster, J. E., Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: A six-month trial. Fertil. Steril. 1998. 70: 107-110.
9. Labrie, F., Diamond, P., Cusan, L., Gomez, J. L., Belanger, A. and Candas, B., Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab. 1997. 82: 3498-3505.
10. Wolkowitz, O. M., Reus, V. I., Keebler, A., Nelson, N., Friedland, M., Brizendine, L. and Roberts, E., Double-blind treatment of major depression with dehydroepiandrosterone. Am. J. Psychiatry 1999. 156: 646-649.
11. Wolkowitz, O. M., Kramer, J. H., Reus, V. I., Costa, M. M., Yaffe, K., Walton, P., Raskind, M. et al., DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled study. Neurology 2003. 60: 1071-1076.
12. Baker, J. R., Jr., Autoimmune endocrine disease. JAMA 1997. 278: 1931-1937.
13. Gurnell, E. M. and Chatterjee, V. K., Dehydroepiandrosterone replacement therapy. Eur. J. Endocrinol. 2001. 145: 103-106.
14. Hunt, P. J., Gurnell, E. M., Huppert, F. A., Richards, C., Prevost, A. T., Wass, J. A., Herbert, J. and Chatterjee, V. K., Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J. Clin. Endocrinol. Metab. 2000. 85: 4650-4656.
15. Arlt, W., Callies, F., van Vlijmen, J. C., Koehler, I., Reincke, M., Bidlingmaier, M., Huebler, D. et al., Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med. 1999. 341: 1013-1020.
16. Corsini, E., Lucchi, L., Meroni, M., Racchi, M., Solerte, B., Fioravanti, M., Viviani, B. et al., In vivo dehydroepiandrosterone restores age-associated defects in the protein kinase C signal transduction pathway and related functional responses. J. Immunol. 2002. 168: 1753-1758.
17. Catania, R. A., Angele, M. K., Ayala, A., Cioffi, W. G., Bland, K. I. and Chaudry, I. H., Dehydroepiandrosterone restores immune function following trauma-haemorrhage by a direct effect on T lymphocytes. Cytokine 1999. 11: 443-450.
18. Miller, R. A. and Chrisp, C., Lifelong treatment with oral DHEA sulfate does not preserve immune function, prevent disease, or improve survival in genetically heterogeneous mice. J. Am. Geriatr. Soc. 1999. 47: 960-966.
19. Maurer, M., Trajanoski, Z., Frey, G., Hiroi, N., Galon, J., Willenberg, H. S., Gold, P. W. et al., Differential gene expression profile of glucocorticoids, testosterone, and dehydroepiandrosterone in human cells. Horm. Metab. Res. 2001. 33: 691-695.
20. Solerte, S. B., Gornati, R., Cravello, L., Albertelli, N., Oberti, S., Perotta, D., Rossi, G. et al., Dehydroepiandrosterone-sulfate (DHEA-S) restores the release of IGF-I from natural killer (NK) immune cells in old patients with dementia of Alzheimer's type (DAT). J. Endocrinol. Invest. 1999. 22: 32-34.
21. high regulatory cells in human peripheral blood. J. Immunol. 2001. 167: 1245-1253.
22. Tan, J. T., Dudl, E., LeRoy, E., Murray, R., Sprent, J., Weinberg, K. I. and Surh, C. D., IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. USA 2001. 98: 8732-8737.
23. Suzuki, T., Suzuki, N., Engleman, E. G., Mizushima, Y. and Sakane, T., Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Ciin. Exp. Immunol. 1995. 99: 251-255.
24. Khorram, O., Vu, L. and Yen, S. S., Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J. Gerontol. A Biol. Sci. Med. Sci. 1997. 52: M1-M7.
25. + regulatory T cells. Nat. Immunol. 2003. 4: 330-336.
26. Hori, S., Nomura, T. and Sakaguchi, S., Control of regulatory T cell development by the transcription factor Foxp3. Science 2003. 299: 1057-1061.
27. Bennett, C. L., Brunkow, M. E., Ramsdell, F., O'Briant, K. C., Zhu, Q., Fuleihan, R. L., Shigeoka, A. O., Ochs, H. D. and Chance, P. F., A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA->AAUGAA) leads to the IPEX syndrome. Immunogenetics 2001. 53: 435-439.
28. Gambineri, E., Torgerson, T. R. and Ochs, H. D., Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr. Opin. Rheumatol. 2003. 15: 430-435.
29. Gregori, S., Giarratana, N., Smiroldo, S., Uskokovic, M. and Adorini, L., A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002. 51: 1367-1374.
30. Gregori, S., Casorati, M., Amuchastegui, S., Smiroldo, S., Davalli, A. M. and Adorini, L., Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 2001. 167: 1945-1953.
31. Barrat, F. J., Cua, D. J., Boonstra, A., Richards, D. F., Crain, C., Savelkoul, H. F., Waal-Malefyt, R. et al., In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 2002. 195: 603-616.
32. Du, C., Guan, Q., Khalil, M. W. and Sriram, S., Stimulation of Th2 response by high doses of dehydroepiandrosterone in KLH-primed splenocytes. Exp. Biol. Med. (Maywood.) 2001. 226: 1051-1060.
33. Duan, R. S., Link, H. and Xiao, B. G., Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats. J. Clin. Immunol. 2003. 23: 100-106.
34. Schifitto, G., McDermott, M. P., Evans, T., Fitzgerald, T., Schwimmer, J., Demeter, L. and Kieburtz, K., Autonomic performance and dehydroepiandrosterone sulfate levels in HIV-1-infected individuals: Relationship to Th1 and Th2 cytokine profile. Arch. Neurol. 2000. 57: 1027-1032.
35. Verthelyi, D. and Klinman, D. M., Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology 2000. 100: 384-390.
36. Solerte, S. B., Fioravanti, M., Vignati, G., Giustina, A., Cravello, L. and Ferrari, E., Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I. J. Clin. Endocrinol. Metab. 1999. 84: 3260-3267.
37. Solerte, S. B., Fioravanti, M., Schifino, N., Cuzzoni, G., Fontana, I., Vignati, G., Govoni, S. and Ferrari, E., Dehydroepiandrosterone sulfate decreases the interleukin-2-mediated overactivity of the natural killer cell compartment in senile dementia of the Alzheimer type. Dement. Geriatr. Cogn. Disord. 1999. 10: 21-27.